Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
The purpose of this study is to evaluate end of shelf-life potency in terms of the immunogenicity and safety of GSK Biologicals\' trivalent MMR vaccine, by comparing it to Merck \& Co., Inc.\'s MMR vaccine, which is approved for use in the United States (US).
Epistemonikos ID: 09d139ba67e3ed8c5cfd2b672eeae5dacf4b2770
First added on: Mar 23, 2020